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H I G H L I G H T S
• Lamotrigine showed disease-modifying and neuroprotective eﬀects in the model.
• Ethosuximide failed to have disease-modifying eﬀects in the model.
• The reduced astrogliosis and neuronal loss were factors of disease-modifying eﬀects.
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A B S T R A C T
Objective: The putative neuroprotective and disease-modifying eﬀects of lamotrigine (LTG) and ethosuximide
(ESM) were investigated in the lithium-pilocarpine (Li-Pc) model of temporal-lobe epilepsy (TLE) in rats. Then,
spontaneous recurrent seizures (SRS), neuronal loss and astrogliosis were assessed.
Methods: Status Epilepticus (SE) was induced by Li-Pc in ﬁve experimental groups: 24 h after SE, all rats received
twice daily either a low (10mg/kg) or high (20mg/kg) dose of LTG, or a low (25mg/kg) or high (50mg/kg)
dose of ESM, or solvent. The sixth group (control) did not receive Li-Pc and was given twice daily injections with
solvent only. Drug administration lasted for 7 d. Rats were systematically observed in the 5th and 6th weeks,
after that the brains were prepared for histology.
Results: LTG dose-dependently decreased the frequency of SRS, and restricted neuronal loss, as well as astro-
gliosis in the hippocampus compared with the untreated SE control group. However, ESM had none of the above-
mentioned eﬀects.
Conclusion: LTG had protective as well as disease-modifying eﬀects in this TLE model. It was revealed that the
disease-modifying eﬀects were accompanied by the prevention of neuronal loss and astrogliosis. ESM was devoid
of antiepileptogenic and its accompanying histological eﬀects in this TLE model, in contrast to the anti-
epileptogenic eﬀects found in the genetic absence epilepsy models, suggesting that diﬀerent mechanisms are
involved in the diﬀerent models for epileptogenesis and antiepileptogenesis.
1. Introduction
Temporal-lobe epilepsy (TLE) is one of the most drug-resistant types
of epilepsy. Thus, this demands other therapeutic approaches than the
classical treatment with ant-epileptic drugs; one of which is the pro-
phylactic treatment aiming at preventing epileptogenesis or disease
modiﬁcation (Schmidt and Löscher, 2005; Dichter, 2009). Various an-
imal models and methods have been used to ﬁnd out disease modifying
medication in TLE, such as electrical or chemical hippocampal or
amygdala kindling (Stratton et al., 2003), febrile seizures (Dubé et al.,
2007), and diﬀerent post-status epilepticus (SE) models (Turski et al.,
1983a,b). The post-SE models come close to being homologous for TLE
(Morimoto et al., 2004), although some of them are also criticized be-
cause of their wide spread extra hippocampus tissue damage (Lévesque
et al., 2016). Rats develop spontaneous recurrent seizures (SRS), hip-
pocampal and extra-hippocampal damage, as well as behavioral and
cognitive alterations resembling the clinical characteristics of TLE after
a systemic injection with the muscarinic cholinergic agonist pilocarpine
(Morimoto et al., 2004).
Older and newer anti-epileptic medications, including lamotrigine
(LTG), have been investigated for their antiepileptogenic or disease
modifying and neuroprotective eﬀects in a variety of TLE models with
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diﬀerent results. LTG demonstrated antiepileptogenic-like eﬀects by
blocking seizure development during treatment period in a rat amyg-
dala (Stratton et al., 2003) and PTZ kindling model (Chen et al., 2017).
However, LTG was given in both studies prior to the daily kindling
sessions and this may have curtailed the intensity and duration of the
after discharge (AD); as a consequence, this might have slowed down
epileptogenesis.
Curtailing rarely occurs in the post-SE models when drug adminis-
tration is initiated after SE onset, or better after SE oﬀset. For example,
Nissinen et al. (2004) attempted to start LTG treatment 2 h after the
induction of electrically induced SE, and their treatment lasted
11 weeks. Antiepileptic eﬀects were found, while there were no anti-
epileptogenic eﬀects in this electrically induced post-SE model.
Curtailing can be fully prevented in post-SE models if treatment
started when SE is completely over, for example 24 h after SE. Here, the
eﬀects of the putative antiepileptogenic action of LTG in the Lithium-
Pilocarpine (Li-Pc) post-SE model, most commonly used for studying
epileptogenesis, were evaluated in rats. In an earlier study performed
by using this model, seizures were counted and histology was carried
out during LTG treatment (Chen et al., 2010) without a wash-out
period, therefore, an antiepileptic action was investigated and estab-
lished.
Antiepileptogenic and disease modifying eﬀects of Ethosuximide
(ESM), a Ca2+ channel blocker, have been described in a genetic type of
absence epilepsy model, rats of the WAG/Rij strain. The age-dependent
increase of spike-wave discharges (SWDs), upregulation of cortical
Na+, and downregulation of HCN channels were diminished as a con-
sequence of early and chronic treatment until 2–4months after stopping
its administration (Blumenfeld et al., 2008; Sarkisova et al., 2010; van
Luijtelaar et al., 2013; Russo et al., 2010). There are also indications
that ESM might play a major role in antiepileptogenesis in the Li-Pc
post-SE model: the RNA and protein of the subtype T-type Ca2+
channel, Cav3.2 was upregulated and caused an increase in T-type Ca2+
currents, in addition to a transitional increase in intrinsic burst ﬁring in
mice (Becker et al., 2008). In the present study, we aimed to ﬁnd out
whether LTG and ESM have neuroprotective and antiepileptogenic or
disease-modifying eﬀects in the Li-Pc post-SE model of TLE.
2. Results
2.1. The eﬀects of LTG and ESM on seizure frequency
Within 5min after intraperitoneal injection of Li-Pc, the rats showed
a shrinking pupil reaction, salivation and diarrhea, as well as facial
clonus, including eye blinks, rhythmic chewing and nodding, in which
forelimb spasms appeared. About 30min after SE, rats developed a
rearing position or tonic-clonic seizures appeared. Here, 58 rats were
used in the experiment. In addition to 8 rats in the control group, 50
rats were injected with Li-Pc. Besides, 6 of the 50 injected rats showed
only seizure stages I-III without SE; 4 of the 50 rats died because of
severe SE; 40 of 50 rats got SE, survived, and then were randomly di-
vided into ﬁve groups, and each group consisted of eight rats.
After the acute phase of SE, the rats entered the static period, which
showed less eating, irritability, and restlessness. 15 days after SE in-
duction, the rats entered the chronic phase. SRS of magnitude III-V
could be observed and continued for 1–2min in the model group. The
duration of seizures varied roughly between 10 and 15 s for rats in the
LTG groups, and frequency of SRS (the number of SRS per week) was
signiﬁcantly and dose-dependently lower compared with the model
group (P < 0.05). The frequency of SRS for both ESM groups did not
signiﬁcantly decrease compared with the model group (See Fig. 1,
P > 0.05).
2.2. The eﬀects of LTG and ESM on hippocampal neurons
The CA3 area contained several Nissl stained neurons (See Figs. 2
and 3). The nuclei were dyed blue and the Nissl stained cell bodies were
abundantly present. The Nissl bodies presented themselves in patches
or in ﬁne granular layers. In the control group, the neurons were packed
Fig. 1. The eﬀects of LTG and ESM on the number of SRS per week (n=8 per
group), as observed during 5 and 6weeks after SE. LTG decreased the frequency
of SRS in a dose-dependent manner, while ESM had no signiﬁcant eﬀect.
*P < 0.05 compared with the model group; #P < 0.05 compared with the
low dose LTG group. Y-axis: the number of SRS per week, mean and standard
deviation (SD) were plotted.
Fig. 2. Hippocampal neurons in CA3 area in diﬀerent groups (n=8 per group),
in which mean and SD were plotted. A: Normal control group; B: Model group;
C: LTG group (10 mg/kg, twice daily); D: LTG group (20 mg/kg, twice daily); E:
ESM group (25mg/kg, twice daily); F: ESM group (50mg/kg, twice daily).
Coronal brain paraﬃn sections (thickness= 4 µm) were examined using light
microscopy (×400 magniﬁcation). In the dorsal of CA3 area, ﬁve non-over-
lapping visual ﬁelds were randomly sampled to count the number of positive
Nissl-stained neurons in each ﬁeld (625 µm2). Scale bar (A, B, C, D, E, F) is
100 µm.
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closely and the edges were clear. In the model group, the neurons were
diﬀusely and sparsely arranged. Dying cells were identiﬁed: the size of
neurons became smaller with a wrinkled cell membrane; the nuclei
were more condense, or the nuclei had disappeared and only a trace of
the membrane of the nuclei was present. The quantiﬁcation revealed
that the number of neurons in the model group was fewer compared
with that in the control group (P < 0.05). The neuronal loss and de-
gree of damage were reduced signiﬁcantly and dose-dependently in the
LTG groups compared with the model group (all P < 0.05). However,
no signiﬁcant diﬀerences were found in the groups receiving ESM
compared with the model group or between the ESM groups
(P > 0.05).
2.3. The eﬀects of LTG and ESM on hippocampal astrogliosis
Glial ﬁbrillary acidic protein (GFAP) staining was performed in
order to evaluate astrogliosis in the CA1 area of the hippocampus. The
number of immune reaction positive cells was fewer (P < 0.05) in the
control group compared with the other groups (except in the higher
dose LTG group). A qualitative impression of the hippocampal astro-
cytes is given in Fig. 4. The number of immune reaction positive as-
trocytes increased in the model group, and the size of the astrocytes
became larger with thicker cell membrane and shorter dendrite branch.
Astrogliosis was remarkably and dose-dependently reduced in the LTG
groups compared with the model group (P < 0.05). However, there
were no signiﬁcant diﬀerences between the rats that were treated with
ESM of between the ESM groups and the model group (P > 0.05, see
Fig. 5).
3. Discussion
The Post-SE Li-Pc model was used to study the eﬀects of two anti-
epileptic drugs on epileptogenesis in TLE. Treatment with two doses of
LTG (20 and 40mg/kg/day) for 7 d, initiated that 1 d after SE, the
number of SRS was reduced dose-dependently. Considering that LTG
was only ﬁrst administered 24 h after SE and the number of SRS was
counted after complete LTG wash-out, our design precluded putative
anti-epileptic eﬀects of the medication. Therefore, it can be concluded
Fig. 3. The eﬀects of LTG and ESM on the number of neurons counted in the
hippocampal CA3 area (n=8 per group), in which mean and SD were plotted.
The number of Nissl stained neurons was signiﬁcantly lower in the model group
compared with the control group. The neuronal loss remained dose-depen-
dently restricted by the intervention with lamotrigine (LTG10 and LTG20, twice
daily), while the ethosuximide (ESM25 and ESM50, twice daily) treated rats did
not diﬀer from the model group. *P < 0.05 compared with the model group;
#P < 0.05 compared with the lower dose LTG group.
Fig. 4. Hippocampal astrogliosis in the CA1 area in diﬀerent groups (n=8 per
group). A: Normal control group; B: Model group; C: LTG group (10mg/kg,
twice daily); D: LTG group (20mg/kg, twice daily); E: ESM group (25mg/kg,
twice daily); F: ESM group (50mg/kg, twice daily). Coronal brain paraﬃn
sections (thickness= 4 µm) were examined using light microscopy (×200
magniﬁcation). In the dorsal of CA1 area, ﬁve non-overlapping visual ﬁelds
were randomly sampled to count positive GFAP-staining astrocytes in each ﬁeld
(1250 µm2). Scale bar (A, B, C, D, E, F): 200 µm. Mean numbers and SD were
plotted.
Fig. 5. The eﬀects of LTG and ESM on the number of astrocytes in the CA1 area
of the hippocampus (n= 8 per group). The number of astrocytes (mean and SD)
was signiﬁcantly increased in the model group compared with the control group
(not indicated), and this eﬀect was reversed by lamotrigine (LTG10 and LTG20,
twice daily) intervention, while ethosuximide (ESM25 and ESM50, twice daily)
had no signiﬁcant eﬀect. *P < 0.05 compared with the model group;
#P < 0.05 indicates that there is a signiﬁcant diﬀerence between LTG10 and
LTG20 groups.
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that the outcome indicated disease-modiﬁcation of LTG in this post-SE
model of TLE. Disease-modifying eﬀects were obtained (Löscher and
Brandt, 2010; Giblin and Blumenfeld, 2010), not complete anti-
epileptogenesis, by this prophylactic treatment in the Li-Pc post-SE
model since a reduction in the number of SRS was found, without a
complete abolishment. Disease modiﬁcation means decreasing the sei-
zure frequency, and/or seizure intensity and/or increasing the latency
for the occurrence of SRS after prophylactic treatment.
Our results with LTG are diﬃcult to be compared with those
achieved by kindling models of TLE, and in some studies (Stratton et al.,
2003; Chen et al., 2017), antiepileptogenesis or disease modifying ef-
fects were suggested. However, in the kindling models, LTG has been
administered immediately prior to the electrical or chemical kindling
sessions (Stratton et al., 2003; Postma et al., 2000; Chen et al., 2017),
therefore, antiepileptic eﬀects were evaluated. Sometimes anti-
epileptogenic eﬀects were suggested based on the results obtained after
a wash-out period, however, they might be fully or partly explained by
an antiepileptic action since the intensity of the kindled seizures might
be less (curtailing) due to the administration of LTG prior to kindling;
consequently, epileptogenesis might be slower. Therefore, a mix of
antiepileptic and antiepileptogenic eﬀects can be suggested to explain
the reduction of kindled seizures. Complete negative eﬀects regarding
antiepileptogenesis of LTG were achieved in a cortical kindling seizure
model in rats (O’Donnel and Miller, 1991), suggesting that diﬀerent
mechanisms are involved in diﬀerent models for epileptogenesis and
antiepileptogenesis.
A single study towards antiepileptogenesis and disease modiﬁcation
used a post-SE model; in this case, SE was elicited by electrical stimu-
lation of the amygdala (Nissinen et al., 2004). However, those authors
could not demonstrate whether LTG had disease modifying or anti-
epileptogenic eﬀects. The chronic LTG treatment was initiated 2 h after
the induction of SE since the mean frequency of seizures, seizure
duration, and seizure intensity did not signiﬁcantly diﬀer between the
LTG and vehicle groups.
There are a few reasons, justifying diﬀerent eﬀects of LTG on anti-
epileptogenesis or disease-modifying in diﬀerent experiments. Firstly,
diﬀerent models were used in these experiments, including kindling
models induced by electrical stimulation of the amygdala or cortex,
chemical kindling models by PTZ, post-SE model induced by electrical
stimulation of the amygdala, and post-SE model induced by Li-Pc.
Secondly, kindling and post-SE models also diﬀered regarding when the
drugs were administered; in the kindling models, drugs were given
prior to the daily kindling sessions, while in the SE models drugs were
often given immediately after the end of SE or during the silent period.
Despite these diﬀerences in the two post-SE models (amygdala stimu-
lation and Li-Pc model), it remains an open question why disease
modiﬁcation was only obtained in the pilocarpine model and not in the
amygdala model.
LTG dose-dependently reduced neuronal loss in the CA3 area of the
hippocampus compared with the model group. We selected the CA3
area based on Liu et al. study (1994) who reported a cell loss in the
Pilocarpine post-SE model in rats, and they also found cell loss in the
CA1 and CA3 areas. In addition, others reported cell loss in the post-SE
models in the CA3 area (Blümcke et al., 2012; Sendrowski and
Sobaniec, 2013). Our data indicated that LTG had a neuroprotective
function, which is also consistent with other researches’ outcomes
(Jung et al., 2006). In the latter study, celecoxib, a selective cycloox-
ygenase-2 inhibitor, attenuated the development of SRS after SE in-
duced by pilocarpine, and also prevented neuronal death and microglia
activation in the CA1 and hilus, suggesting neuroprotection. A previous
study emphasized that especially neurons in the hippocampal hilus are
vulnerable for seizures (Buckmaster and Jongen-Rêlo, 1999). However,
neuroprotection is not always accompanied by antiepileptogenesis or
disease-modiﬁcation. Halonen et al. (2001) showed that LTG has neu-
roprotective eﬀect, without any eﬀect on the number or duration of
behavioral seizures. In addition, Maj et al. (1998) reported that pre-
treatment of rats with LTG before kainate administration could prevent
hippocampal cell loss, while could not prevent seizures. It indicated
that neuronal loss of hippocampal cells is only one kind of structural
change, accompanying by epileptogenesis or disease-modiﬁcation,
however, it does not necessarily imply that the structural changes in the
hippocampus necessarily cause seizures to be occurred.
LTG dose-dependently decreased astrogliosis induced by the appli-
cation of our SE protocol. Astrocytic dysfunction may also play a sig-
niﬁcant role in epileptogenesis by reducing the clearance of extra-
cellular potassium underlying neuronal hyperexcitability and network
synchronization (Yaron et al., 2009). Whole-cell patch-clamp record-
ings from astrocytes further suggested that astrogliosis in a mouse
model of genetically induced, widespread chronic astrogliosis causes an
impaired astrocytic glutamate uptake, which is in parallel with heigh-
tened excitability and the occurrence of seizures (Robel et al., 2015).
Whether neuronal death and astrogliosis are the key elements in
epileptogenesis should be further elucidated. A number of previous
studies (e.g., Halonen et al., 2001) have shown that these features do
not play a major role in epileptogenesis. Moreover, experiments con-
ducted with N-methyl-D-aspartate (NMDA) receptor antagonists in a rat
kainate-induced SE model showed that a single dose of the NMDA re-
ceptor blocker dizocilpine (MK801) given 90min after SE resulted in
hippocampal neuroprotection, while it did not prevent the development
of spontaneous seizures, suggesting that structures not protected by
dizocilpine may play a major role in the genesis of these seizures, or
that epileptogenesis is not the consequence of structural lesions in the
limbic system (Brandt et al., 2003). On the other hand, it cannot be
excluded that the combined prevention of hippocampal neuronal death,
astrogliosis and increased mossy ﬁber sprouting and most likely some
other factors may restrict the chance that spontaneous seizures start to
emerge.
Ca2+ ions and Ca2+ channels might play a role in epileptogenesis;
preclinical data identiﬁed T-type Ca2+ channel Cav3.2 as a central
player in epileptogenesis in the mice Li-Pc post-SE model, and SE
caused a transient transcriptional upregulation of Cav3.2 channels
(Becker et al., 2008), producing an increase in T-type Ca2+ currents.
Importantly, ESM is known to block T-type Ca2+ currents (Gomora
et al., 2001), and it has disease modifying properties, as was previously
shown in a genetic epilepsy model (Russo et al., 2010). However, ESM
failed to protect rats against epileptogenesis, and there were neither
signs of disease modiﬁcation, nor signs of neuroprotection in our ex-
periment. The highest dose of ESM was 100mg/kg/day, divided over
two injections of 50mg/kg/per day. Russo et al. (2010) mentioned that
80mg/day/kg ESM might already yield antiepileptogenesis in WAG/Rij
rats, however, the better antiepileptogenic eﬀects were found with
300mg/kg/day. Therefore, the lowest dose (50mg/kg/day) might have
been very low, and the double dose might not be yielded anti-
epileptogenic eﬀects. On the other hand, the duration of the twice-daily
period of ESM administration might have be very short, although that
would be long enough in the case of LTG; another issue is whether the
mechanisms of antiepileptogenesis in absence epilepsy are identical to
the mechanisms in epileptogenesis in the Li-Pc post–SE model. ESM is
known not to be eﬀective as an antiepileptic drug in models other than
the absence models, and it currently seems that it lacks anti-
epileptogenic or disease-modifying eﬀects and does not have a neuro-
protective action in this post-SE model of TLE when administered 24 h
after SE. These results extend the results achieved by Leite and
Cavalheiro (1995), using the Li-Pc model. They administered a high
(400mg/kg, i.p.) dose of ESM twice daily for 2 weeks during the SRS
period, and found that it might be inactive against these seizures.
There are a number of limitations in our study. Firstly, we did not
determine the blood levels of drugs during administration. Secondly, no
electroencephalography (EEG) was carried out to identify epileptic
activity during SE and the period of the SRS.
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4. Conclusions
LTG treatment has both neuroprotective and disease-modifying ef-
fects in the post-SE model of TLE induced by Li-Pc. We propose that the
disease-modifying eﬀects occur if the reduction of astrogliosis and
neuronal loss, but also other factors such as mossy ﬁber sprouting
(Buckmaster, 2014), a loss of GABA-ergic neurons in the hilus
(Buckmaster and Jongen-Rêlo, 1999) underlying the presence of the
SRS, or dysregulation of an ion channel or neurotransmitter receptor, or
alternations in signaling pathways, might be successfully prevented or
repaired by treatment, although the prevention of hippocampal neu-
ronal death does not seem a suﬃcient or necessary condition to prevent
spontaneous seizures. ESM did not eﬀect on any of these variables. In
the future, it should be investigated whether or not LTG has disease-
modifying eﬀect aiming to prevent neuronal loss and astrogliosis in
models of traumatic brain injury, one of the most common brain insults.
5. Experimental procedures
5.1. Animals and drugs
The study was performed in female SD rats (n= 58), weighing
150–200 g, which were provided by Shanxi Medical University. The rats
were maintained under standard laboratory conditions with a natural
light-dark cycle. They were given a standard pellet diet and tap water
ad libitum. LTG was purchased from Glaxo Operations UK Ltd and pi-
locarpine from Sigma Chemical Co. (St. Louis, MO, USA). ESM was a
gift from Katwijk Chemie B.V., the Netherlands. Animal welfare pro-
cedures were in accordance with common published guidelines and no
more animals were used than necessary.
5.2. Lithium Chloride-Pilocarpine epilepsy rat model
Rats were pretreated with lithium chloride (127mg/kg, i.p., Sigma,
St. Louis, MO) and methylscopolamine-bromide (1mg/kg, i.p., Sigma)
18 h and 30min before pilocarpine administration, respectively.
Pilocarpine hydrochloride (30mg/kg, i.p., Sigma) was injected to
trigger SE. Repeated doses of pilocarpine hydrochloride 10mg/kg were
then administered every 30min until stage 4 seizures developed ac-
cording to Racine’s scale (Racine, 1972). The dose of pilocarpine hy-
drochloride never exceeded 60mg/kg. Diazepam (10mg/kg, i.p.
Samjin, Seoul, Korea) was injected 1 h after SE in order to terminate
seizure activity: its administration was repeated until SE was
terminated as based on visual observations. Although it might be dif-
ﬁcult to decide whether the animals had still had SE after the admin-
istration of diazepam, the SE rats were randomly divided across the ﬁve
SE groups and at forehand there is no reason to assume that the lack of
EEG control privileged any of the ﬁve conditions and that this has in-
ﬂuenced the diﬀerences between the groups.
SRS were observed by video in all rats during the 5th and 6th week
after SE and were scored according to Racine’s scale: 0= no convulsive
behavior; 1= sedation, less activity but revival of righting reﬂex;
2= facial clonus or head nodding; 3= forelimb clonus; 4= rearing,
animal in a standing posture aided by tail and laterally spread hind
limbs showing increased tonus; 5= tonic-clonic seizure.
5.3. Study design
Eight rats were selected randomly and served as a control group.
The other rats were used for the induction of SE: after successful in-
duction of SE, these rats were randomly divided into ﬁve groups, eight
rats per group. The untreated “normal” control group was given the
same volume of saline instead of Pilocarpine and Lithium chloride and
for the next seven days, and it was given saline twice a day by gavage
instead of LTG or ESM. The group that received solvent instead of LTG
or ESM was called the “model” group. The low and high dose LTG
groups were given LTG (10 and 20mg/kg respectively) twice daily by
gavage. The low and high dose group of ESM was given twice daily
(i.p., 25mg/kg and 50mg/kg respectively). Both drugs were adminis-
tered for the ﬁrst time 24 h after SE and the administration was con-
tinued for seven consecutive days (See Fig. 6).
5.4. Behavioral observations
Here, 2 weeks after SE, the pilocarpine treated rats started to show
SRS, which was called the chronic phase. Rats were monitored using a
video recorder (24 h per day) from the 5th to the end of the 6th week
after SE to evaluate the number, duration and intensity of the SRS.
5.5. Hippocampal staining
After the end of the observation period, all rats were anesthetized
and intracardially perfused with 4% paraformaldehyde according to a
ﬁxation protocol. The ﬁxated brain was coronally sliced for paraﬃn
sections (4 µm thick). Six sections came from one rat. Three paraﬃn
sections were used for Nissl staining using standard protocols based on
Fig. 6. Schematic illustration of the experimental protocol used in the study.
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the description by Kobayashi and Buckmaster (2003). Besides, 3 par-
aﬃn sections were made for GFAP staining, using standard protocols
previously described by Panagiota et al. (2010).
5.6. Analysis of image data
Nissl staining sections of hippocampus CA3 area were examined
using light microscopy (×400 magniﬁcation). In the dorsal section of
the CA3 area, ﬁve non-overlapping visual ﬁelds were randomly sam-
pled to count the number of positive Nissl-staining neurons in each ﬁeld
(625 µm2). Next, the average number of Nissl-stained neurons per an-
imal and per group (ﬁve experimental groups, one control group) was
calculated.
The astrocytes stained by GFAP in CA1 region of the hippocampus
were also examined using a light microscope (×200 magniﬁcation). In
the dorsal of CA1 area, ﬁve non-overlapping visual ﬁelds were ran-
domly sampled and the number of positive GFAP-staining astrocytes in
each ﬁeld (1250 µm2) were counted. The average number of GFAP-
staining astrocytes across the ﬁve ﬁelds was calculated, next the
mean ± SD of the number of labeled astrocytes were calculated for all
six groups.
The counting of both Nissl stained neurons and GFAP labeled as-
trocytes was carried out by trained assistants using the double-blind
method.
5.7. Statistical analysis
Data were expressed as mean ± standard deviation (SD). The sta-
tistical analyses were performed using SPSS 17.0 software (IBM,
Armonk, NY, USA). One-way analysis of variance (ANOVA) was used to
intra-groups comparisons followed by Fisher’s Least Signiﬁcant
Diﬀerence (LSD) test. P values < 0.05 were considered statistically
signiﬁcant.
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